Enterprise Value

685.7B

Cash

1.997B

Avg Qtr Burn

-163.4M

Short % of Float

0.05%

Insider Ownership

0.00%

Institutional Own.

54.50%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
VYVGART Hytrulo (SC Efgartigimod) Details
MYASTHENIA GRAVIS, Autoimmune disease

Approved

Quarterly sales

Efgartigimod Details
Mucosal Pemphigus Vulgaris

Phase 3

Data readout

Efgartigimod Details
Primary immune thrombocytopenia

Phase 3

Data readout

Efgartigimod Details
Chronic inflammatory disorder

Phase 3

Update

Empasiprubart Details
Neuropathy, Neuromuscular disease, Multifocal motorneuropathy

Phase 2

Data readout

Efgartigimod Details
Sjögren-Larsson Syndrome

Phase 2

Data readout

Efgartigimod Details
Post-COVID Postural Orthostatic Tachycardia Syndrome

Phase 2

Data readout

Empasiprubart Details
Delayed graft function

Phase 2

Initiation